Energetic cost of breathing, body composition, and pulmonary function in horses with recurrent airway obstruction by Mazan, M. R. et al.
Energetic cost of breathing, body composition, and pulmonary function
in horses with recurrent airway obstruction
Melissa R. Mazan,1 Edward F. Deveney,2 Shane DeWitt,1 Daniela Bedenice,1 and Andrew Hoffman1
1Department of Clinical Sciences, Tufts University School of Veterinary Medicine, North Grafton 01536, and
2Physics Department, School of Arts and Sciences, Bridgewater State College, Bridgewater, Massachusetts 02325
Submitted 17 June 2003; accepted in final form 9 February 2004
Mazan, Melissa R., Edward F. Deveney, Shane DeWitt, Daniela
Bedenice, and Andrew Hoffman. Energetic cost of breathing, body
composition, and pulmonary function in horses with recurrent airway
obstruction. J Appl Physiol 97: 91–97, 2004. First published February
13, 2004; 10.1152/japplphysiol.00629.2003.—This study was con-
ducted to determine whether horses with naturally occurring, severe
chronic recurrent airway obstruction (RAO) 1) have a greater resting
energy expenditure (REE) than control horses, 2) suffer body mass
depletion, and 3) have significantly decreased REE after bronchodi-
lation and, therefore, also 4) whether increased work of breathing
contributes to the cachexia seen in some horses with RAO. Six RAO
horses and six control horses underwent indirect calorimetric mea-
sures of REE and pulmonary function testing using the esophageal
balloon-pneumotachograph method before and after treatment with
ipratropium bromide, a parasympatholytic bronchodilator agent, at
4-h intervals for a 24-h period. Body condition scoring was per-
formed, and an estimate of fat mass was determined via B-mode
ultrasonography. O2 and CO2 fractions, respiratory airflow, respira-
tory rate, and pleural pressure changes were recorded, and O2 con-
sumption, CO2 production, REE, pulmonary resistance, dynamic
elastance, and tidal volume were calculated. In addition, we per-
formed lung function testing and calorimetry both before and after
sedation in two control horses. RAO horses had significantly lower
body condition scores (2.8  1.0 vs. 6.4  1.2) and significantly
greater O2 consumption than controls (4.93  1.30 vs. 2.93  0.70
ml kg1 min1). After bronchodilation, there was no significant
difference in O2 consumption between RAO horses and controls,
although there remained evidence of residual airway obstruction.
There was a strong correlation between O2 consumption and indexes
of airway obstruction. Xylazine sedation was not associated with
changes in pulmonary function but did result in markedly decreased
REE in controls.
indirect calorimetry; naturally occurring disease; resting energy ex-
penditure; oxygen consumption; ipratropium bromide
RECURRENT AIRWAY OBSTRUCTION (RAO), also known as heaves,
is a common disease in horses that is characterized by revers-
ible airway obstruction, bronchospasm, and airway hyperreac-
tivity attributable to inflammation of the airways, mucus pro-
duction, and thickening of airway walls (44). Putative causes
include aeroallergens, especially the organic dusts, endotoxin,
molds, and spores found in even clean stables (59, 34, 55).
Even during clinical remission, horses with RAO have resid-
ual, subclinical airway inflammation, obstruction, and hyper-
responsiveness (42). RAO is often compared with asthma (7);
however, in its more chronic stages, it bears strong clinical
resemblance to chronic obstructive lung diseases in the human:
features shared by both RAO and chronic obstructive pulmo-
nary disease (COPD) include bronchiolitis with peribronchio-
lar accumulation of neutrophils (9, 17), upregulation of both
IL-8 (16, 50) and NF-B, stimulating chronic inflammation,
and airway reactivity (54), leading to limitations in airflow (2).
Clinicians note that a subset of RAO horses suffers depletion of
body mass; however, the physiology of cachectic RAO horses
has not been described. Similarly, a subset of people with
chronic obstructive lung diseases has been shown to experience
tissue wasting; this is associated with both an increase in
resting energy expenditure (REE) and the O2 cost of ventilation
(29, 49). Although the mechanical work of breathing in RAO
horses has been demonstrated to be greater than in normal
horses (36), whether this causes cachexia is unclear. Our
laboratory previously reported that acute bronchodilation of
mildly affected RAO horses with the 2-adrenoceptor agonist
albuterol sulfate results in small decreases in both respiratory
resistance and REE, without any correlation between the de-
gree of bronchodilation and the decrease in REE (32). To
determine the contribution of pulmonary dysfunction to tissue
wasting in RAO horses, we sought to measure pulmonary
function, energy expenditure, body condition score, and body
composition in a group of horses with naturally occurring,
severe, and chronic RAO both compared with a group of
control horses and after bronchodilation. To effect bronchodi-
lation, we chose ipratropium bromide (IB), a parasympatho-
lytic bronchodilator that has no demonstrable thermogenic
effects in other species (6, 35, 37) and that has been shown to
elicit bronchodilation in RAO horses (13, 43).
We hypothesized that horses with chronic, severe, naturally
occurring RAO and loss of body condition would have ele-
vated REE due to impaired pulmonary function and that
bronchodilation would both improve pulmonary function and
decrease REE. Conversely, we hypothesized that it was possi-
ble that underweight horses, like some underweight human
COPD patients, might have a reduction in fat-free mass with
subsequent decrease in REE, because of the fact that the
majority of REE is derived from fat-free mass (51).
MATERIALS AND METHODS
All procedures described were approved by the Institutional Ani-
mal Care and Use Committee at Tufts University.
Animals
Six client-owned horses with spontaneously occurring RAO, in-
cluding three mares and three geldings; and six healthy female horses
were evaluated (Table 1). RAO horses were chosen on the basis that
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they had a documented history of RAO (per a referring veterinarian)
that included recurring reversible episodes of increased expiratory
effort, nasal flaring, coughing, and nasal discharge, over a period of at
least 2 yr, without evidence of infection or any other chronic systemic
disease within the prior 4 mo. All RAO horses had an evident “heave”
line. Control horses had no history or clinical evidence of respiratory,
infectious, or chronic systemic disease. None of the horses had been
treated with any corticosteroid for 4 wk or with any bronchodilator for
2 wk before the commencement of the study.
Study Design
All testing took place within a 1-yr period. Horses were admitted
on the morning of day 1 to the Lung Function Laboratory at the
Hospital for Large Animals at Tufts University School of Veterinary
Medicine, where they were housed in a clean hospital environment,
bedded on shavings, and fed hay. On day 1, body condition scoring
and physical examination were performed. Horses were fasted for
12 h before the commencement of physiological testing on the
morning of day 2. Each horse was administered xylazine (0.5 mg/kg
iv, Rompun, Bayer, Shawnee Mission, KS) and allowed to rest for 10
min (32). Then, O2 consumption (V˙ O2) and CO2 production (V˙ CO2)
were measured, and respiratory quotient (RQ) and REE were calcu-
lated by use of indirect calorimetry during a 15- to 20-min period (10
min for equilibration and 5–10 min for data collection). Thirty
minutes after administration of xylazine, lung mechanics were mea-
sured by use of the esophageal balloon-pneumotachograph method;
data were recorded during a period of 3–5 min (33). Horses were then
given aerosolized IB (180 g, Atrovent, Boehringer Ingelheim, In-
gelheim, Germany). The first horse did not show appreciable bron-
chodilation at 1 and 2 h [10% decrease in pulmonary resistance (RL)
or 10% increase in dynamic compliance (Cdyn)]; thus the protocol
was amended such that IB administration was repeated every 4 h for
a 24-h period. On day 3, after 24 h of IB treatment, horses were again
sedated with xylazine as above, and measurements of lung mechanics
and indirect calorimetry were repeated between 30 and 60 min after
administration of the final dose of IB.
In addition, to determine the effect of xylazine on baseline calo-
rimetry and pulmonary function measurements, two control horses
underwent baseline calorimetry and pulmonary function testing as
described below, both unsedated and after sedation with xylazine (0.5
mg/kg body wt iv). In specific, each horse underwent calorimetry
unsedated and was then instrumented as described below for pulmo-
nary function measurements, and baseline measurements were made.
The horse was then administered xylazine, and pulmonary function
measurements were repeated. Immediately after pulmonary function
testing, calorimetry testing was repeated. Once the horse was sedated,
both pulmonary function testing and calorimetry were completed
within a 30-min period (5 min for pulmonary function measurement
and 15–25 min for calorimetry). The horses stood quite still but were
extremely alert while calorimetry was performed.
Assessment of Sedation
During measurement of REE, sedation was judged to be adequate
when there was a lack of voluntary movement (e.g., head tossing, foot
movements, tail swishing) throughout the testing period and when
horses were quiet and nonresponsive to minor noises and movements
within the laboratory (32).
Body Condition Scoring
The procedure was adapted from that described by Henneke et al.
(18). It involved the use of a combination of visual inspection and
palpation to rate each horse from extremely thin (score of 1) to
extremely fat (score of 9), with a score of 5 being ideal.
Determination of Fat-Free Mass
Rump fat thickness was calculated by the method of Kane et al.
(20). Briefly, the position of maximal fat thickness at a site 5 cm
lateral to the midline of the rump was determined by B-mode ultra-
sonography, and maximal fat thickness was measured at this site.
Percent fat was estimated from the equations of Kearns et al. (21).
%Fat 2.47 5.47 [rump fat (in cm)]
Fat mass  (total body mass in kg) (%fat)
FFM  total body mass fat mass
Measurement of Lung Mechanics
During all measurements of lung mechanics and calorimetry, the
horses’ heads were kept elevated at an angle at least 180° to the
horizontal, to decrease the likelihood of upper airway obstruction
(25). The horse wore an airtight Plexiglas mask, affixed above the
nostrils with a latex shroud, which was attached to the pneumotacho-
graph. The pneumotachograph (Fleisch no. 5, OEM Medical, Lenoir,
NC) was calibrated by use of a precision syringe (3-liter volume
syringe, Hans Rudolph, Kansas City, MO). The pneumotachograph
was connected via tubing to a differential pressure transducer (DP45-
14, Validyne Engineering). An esophageal balloon catheter was
placed to the level of the midthorax and connected to a differential
pressure transducer (DP45-28, Validyne Engineering) and amplified.
The opposite pole of the pressure transducer was connected to a side
port in the gas-collection mask to obtain transpulmonary pressure
measurements. Ten-breath averages for respiratory rate (RR), tidal
volume (VT), RL, dynamic elastance (Edyn), and change in pleural
pressure (dPpl) were recorded on a personal computer by using data
acquisition software (XA Biosystems version 2.2, Buxco Electronics,
Sharon, CT).
Indirect Calorimetry
The open-flow indirect calorimetry system used in the study has
been previously described (32). Briefly, air was drawn through a rigid
open face mask via flexible airway tubing (outside diameter, 7 cm), by
using a vacuum (5-gallon vacuum, Shop-Vac, Williamsport, PA)
located outside of the room. Flow was regulated with a rotameter
equipped with a control valve (Flometer 70-670 L, Brooks Instrument,
Emerson Electric, Hatfield, PA). Flow through the system was be-
tween 450 and 650 l/min, depending on the size of the horse, and
allowed all of the expired air to be drawn into the mask. A 200-liter
mixing chamber was interposed between the horse and gas analyzers.
Air was drawn through the mixing chamber, traversing two plastic
plates spaced 30 cm apart. Each plate contained nine circular openings
that were 8 cm in diameter and located at regular intervals. An aliquot
of the mixed-air sample emanating from the mixing chamber was
diverted to a sampling pump with a flowmeter-needle valve assembly
to control sample flow through the sensor cells (R-1 Flow Control,
AEI, Pittsburgh, PA), which was then split and metered to the CO2
analyzer (Ametek model CD-3A, AEI) and O2 analyzer (Ametek
S-3A, AEI). Before entering the O2 and CO2 analyzers, the air sample
traversed a drying column that consisted of anhydrous calcium sulfate.
O2 and CO2 fractions were measured continuously. N2 dilution and




Body condition score (1–9) 2.81.0* 6.41.2
Weight, kg 411.463.8* 466.855.0
Fat-free mass, kg 370.350.9 377.238.4
Percent fat, % 9.662.99* 19.013.33
Values are means  SD for 6 horses in each group. RAO, recurrent airway
obstruction. *Significantly different from controls, P  0.05.
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CO2 infusion were used to calibrate the open-flow calorimetry system
using the procedures of Fedak et al. (15). Before the experiment, N2
and then CO2 were bled into the system at 40 and 15 l/min (ATPD),
respectively; total flow was held the same as during the experiment
(for the average horse, 500 l/min) (15). Flow rates for N2 and CO2
were measured using a precision, custom-designed, dual N2-CO2
flowmeter (Brooks Instruments, accuracy 1%). All volumes were
corrected on the basis of standard temperature and pressure (dry). A
minimum of 10 min was allowed for equilibration, at which time the
system had reached a steady state, defined as a time when the horse
stood quietly, with a relaxed posture, and without apparent movement,
and with20% deviation from the means for V˙ O2. Once a steady state
was achieved, data were collected for an additional 5–10 min for use
in calculating mean V˙ O2 and mean V˙ CO2 for the period. Analog
signals from the gas analyzers were digitized and processed by use of
a computer and custom-written software (LabVIEW, National Instru-
ments, Austin, TX). V˙ O2 and V˙ CO2 were subsequently expressed as
milliliters per kilogram per minute. Values for REE were cal-
culated from mean V˙ O2 and V˙ CO2 by use of the abbreviated Weir
equation (58):
REE (Mcal/day)  3.94V˙ O2 1.1V˙ CO2	 1.44
Administration of Aerosolized Drug
IB was administered by use of an aerosolizing face mask system.
This system consisted of a well-fitting face mask with inhalation and
exhalation valves and a holding chamber (Aeromask, Canadian Mon-
aghan, Trudell Medical International, London, ON, Canada). Before
administration of ipratropium (18 g/actuation), the metered-dose
inhaler was shaken for 1 min, followed by a single primer actuation.
The metered-dose inhaler was then attached to the holding chamber
and was actuated at end expiration. A total of 10 actuations were
performed with 30-s intervals between each actuation (total of 180 g
of ipratropium delivered). This dose is in accordance with other doses
that have been effective in eliciting bronchodilation in horses with
RAO (14, 43).
Statistical Analysis
Data are reported as means  SD. A general linear model, with
heaves and treatment as main effects, was used to determine whether
there were significant differences between and within the groups
(heaves and control) before and after treatment with ipratropium.
Spearman’s correlation coefficient was used to determine whether




RAO horses were significantly thinner than control horses
on the basis of body condition score, body weight (kg), and
percent fat. There was no significant difference in fat-free mass
between the two groups. RAO horses were significantly older
than control horses (Table 1).
Baseline Calorimetry Data
RAO horses had higher REE, V˙ O2, and V˙ CO2 than control
horses, but there was no significant difference in RQ between
the two groups (Table 2). V˙ O2 in control horses was in accord
with resting values previously reported in the literature (3, 22,
19, 24).
Baseline Pulmonary Function Data
RAO horses had significantly higher RR, maximal dPpl,
Edyn, and RL, and significantly lower VT than control horses
(Table 3).
Effect of Repeated Administration of IB Over 24 h
Calorimetry. All RAO horses had a decrease in REE, V˙ O2,
and V˙ CO2 (Tables 2 and 4), with a mean decrease of 26.42 
21.2, 26.46  20.99, and 23.68  30.05%, respectively, after
bronchodilation with IB, but control horses had no significant
changes (Table 2). RQ was not significantly different after
treatment. In contrast to the marked difference in V˙ O2, V˙ CO2,
and REE between the two groups at baseline, posttreatment
values were not different between the two groups (Table 2).
Pulmonary function. All RAO horses showed evidence of
bronchodilation after treatment with IB, with mean decreases
in RL, Edyn, dPpl, and RR of 35.95  14.19, 38.28  20.14,
Table 2. Calorimetry data for RAO and control horses both before and after treatment for 24 h with IB
RAO Baseline RAO Posttreatment Control Baseline Control Posttreatment
V˙ O2, mlkg1min1 4.931.13† 3.460.80*† 2.930.70 3.000.62
V˙ CO2, mlkg1min1 3.491.31† 2.521.67* 2.140.76 2.750.32
REE, Mcal/day 13.341.67† 9.703.12* 9.483.04 10.122.61
RQ (V˙ CO2/V˙ O2) 0.720.32 0.730.40 0.720.17 0.940.10
Values are means  SD. IB, ipratropium bromide; V˙ O2, O2 consumption; V˙ CO2, CO2 production. *Significantly different from baseline value, P  0.05.
†Significantly different from control baseline, P  0.05.
Table 3. Pulmonary function data for RAO and control horses both before and after treatment for 24 h with IB
RAO Baseline RAO Posttreatment Control Control Posttreatment
RR, breaths/min 24.78.6† 15.53.6*†‡ 9.32.0 10.23.5
VT, liter 4.360.79† 5.520.70*†‡ 6.870.83 6.501.03
dPpl, cmH2O 27.4911.67† 13.944.60*†‡ 7.061.87 6.021.52
RL, cmH2O  l1  s 1.900.74† 1.190.42*†‡ 0.710.19 0.580.12
Edyn, cmH2O/l 2.201.59† 1.190.77*†‡ 0.540.12 0.480.10
Values are means  SD. RR, respiratory rate; VT, tidal volume; dPpl, change in pulmonary pressure; RL, lung resistance; Edyn, dynamic elastance.
*Significantly different from baseline value, P  0.05. †Significantly different from control baseline, P  0.05. ‡Significantly different from control
posttreatment, P  0.05.
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47.42  7.12, and 29.73  28.48%, respectively. Control
horses had no significant changes (Table 3).
Correlations
Calorimetry and pulmonary function. V˙ O2 in RAO horses
correlated strongly with Edyn (Fig. 1) and RL (Fig. 2).
Calorimetric and pulmonary function measurements in two
control horses with and without xylazine. The data are not
sufficient to support statistical analysis; nonetheless, V˙ O2 (Fig.
3), V˙ CO2, and REE were markedly lower in control horses after
sedation with xylazine (Table 5). After sedation, control horses
had only small changes in pulmonary function testing, includ-
ing a mild decrease in Cdyn, and a moderate increase in RL in
one horse. In addition, there were small changes in VT, RR, and
dPpl after sedation in the control horses (Table 5)
DISCUSSION
This study presents the novel finding that horses with
marked, chronic, naturally occurring RAO have significantly
greater V˙ O2 and V˙ CO2, owing to increased energy demands,
than do control horses (Table 2). In addition, these RAO horses
have less fat (with consequently lower body condition scores)
than do controls (Table 1). Bronchodilation over a 24-h period
resulted in significantly decreased REE (Tables 2 and 4).
Our findings concerning increased RL, Edyn, VT, RR, and
maximal dPpl in horses with RAO accord with previous reports
(36, 44, 47). In our laboratory’s previous study, although we
observed a decrease in REE with bronchodilation, we were not
able to correlate baseline measures of lung function in RAO
horses with energy expenditure (32). In contrast, in our present
study, we find strong correlation between baseline measures of
energy consumption and pulmonary function in RAO horses
(Figs. 1 and 2), similar to humans with chronic airflow ob-
struction (12). Likewise, our findings concerning the efficacy
of IB in eliciting bronchodilation are consistent with prior
reports on the effects of parasympatholytic agents in RAO
horses (5, 14, 39, 43); namely, IB elicited significant bron-
chodilation without returning pulmonary function to control
values. This lack of return to control values is likely due to the
residual obstruction that remains in RAO horses during clinical
remission, because of mucus plugging airways, inflammatory
changes, and gas trapping, even after relief of acute broncho-
spasm (42). Contrary to earlier reports of maximum bronchodi-
lation with aerosolized ipratropium within 1 h (14), we found
that the first horse did not show appreciable bronchodilation at
1 and 2 h. However, there was a considerable increase in
indexes of bronchodilation at 24 h. We theorize that the
heterogeneous pathology of RAO (28) contributed to uneven
ventilation with consequent uneven aerosol deposition and thus
inadequate bronchodilation (57); this was likely partially
amended by repeated administration of drug leading to increas-
ing bronchodilation over a 24-h period. Consistent with our
laboratory’s previous report (32), we found that improved
pulmonary function in RAO horses is accompanied by a
decrease in REE (Tables 2–4). In contrast to our previous
study in which albuterol, a thermogenic bronchodilator, re-
sulted in a 10% decrease in V˙ O2, V˙ CO2, and REE, in our
present study treatment with IB, a nonthermogenic bronchodi-
lator (6, 35, 37), resulted in a far more striking reduction in
REE, V˙ O2, and V˙ CO2, with all horses experiencing 
10%
change in V˙ O2 and REE (Table 4).
Because horses breathe around, not at, functional residual
capacity (23), we were not able to obtain measurements of
end-expiratory lung volume and therefore were not able to
document the presence of hyperinflation. However, horses with
RAO have been shown to have increased an increased func-
tional residual capacity due to hyperinflation (27), as well as
Fig. 1. Relationship between dynamic elastance (Edyn) and O2 consumption
(V˙ O2). Spearman’s rank correlation coefficient (Rs)  0.886, P  0.009. },
Horses with recurrent airway obstruction (RAO), no treatment.
Fig. 2. Relationship between lung resistance (RL) and V˙ O2. Rs  0.771, P 
0.036. }, Horses with RAO, no treatment.
Table 4. Individual data for REE and V˙ O2 in RAO horses









Horse 1 pre 5.600.12 14.890.39 8.32
Horse 1 post IB 4.661.16 12.442.06
Horse 2 pre 4.421.14 11.252.06 7.56
Horse 2 post IB 3.690.95 8.782.01
Horse 3 pre 4.340.56 14.061063.34 10.19
Horse 3 post IB 3.160.1 10.022.36
Horse 4 pre 6.951.20 14.572.56 6.70
Horse 4 post IB 2.210.95 4.771.79
Horse 5 pre 4.290.15 13.440.69 9.39
Horse 5 post IB 3.720.15 11.760.69
Horse 6 pre 3.990.49 11.811.27 9.64
Horse 6 post IB 3.320.45 10.451.27
Mean  SD baseline pre 4.931.13 13.341.49 8.631.34
Mean  SD baseline post 3.460.80 9.702.74
Values are means SD. pre, Before treatment; post, after treatment. Resting
energy expenditure (REE) is also calculated according to National Research
Council (NRC) recommendations for REE in mature horses, according to each
horse’s weight. REE according to NRC recommendations: REE (Mcal/day) 
[0.975  (0.21  body wt kg)] 1,000 (38).
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increased RRs accompanied by increased peak inspiratory and
expiratory flow rates (46). In human asthmatic subjects, hyper-
inflation has been shown to result in an unfavorable length-
tension relationship of the respiratory muscles (31) as well as
resulting in increased dead space, with accompanying in-
creased ventilatory demands and work of breathing (8). Like-
wise, it is probable that these RAO horses have increased V˙ O2
owing to increased resistance in both the large and small
airways, as well as obstruction of small airways, resulting in
hyperinflation with concomitant decreased vital capacity, in-
creased work of gas compression, and possibly increased
inspiratory load.
Although we were unable to completely bronchodilate the
RAO horses in this study, nonetheless we conclude that the
increased REE due to the energy cost of breathing associ-
ated with airway obstruction is a key contributor to the
cachexia of RAO.
A potential source of error in this study is the use of xylazine
hydrochloride as a sedative. We found sedation to be necessary
to carry out testing, because we were using client-owned
animals unaccustomed to the Lung Function Laboratory.
Nonetheless, it is important to note that xylazine has been
found to cause changes in lung mechanics in horses without
history of respiratory disease (25, 26) and in ponies with
preexistent bronchoconstriction (4). Lavoie and colleagues
(25) showed that changes in esophageal balloon pressure and
respiratory resistance were largely dependent on head position;
that is, if the head was allowed to rest at an angle 180° to the
horizontal, both esophageal balloon pressures and resistance
tended to increase. To lessen this effect of sedation in our
study, we took care that the head was never allowed to rest at
an angle 180° to the horizontal. In a previous study (32), our
laboratory had confronted the question of the stability of
calorimetric measurements and measurements of respiratory
system resistance using the forced oscillatory technique in
horses sedated with xylazine during a 45-min testing period
and found that V˙ O2, V˙ CO2, REE, and respiratory system resis-
tance did not change significantly during this time. We did not,
however, investigate the stability of lung mechanics using the
esophageal balloon-pneumotachograph method. In our present
study, we examined both lung mechanics and energy expendi-
ture in control horses, both with and without sedation with
xylazine, and found that whereas sedation was associated with
a large decrease in V˙ O2 and REE, lung mechanics were not so
associated, with the exception of a moderate increase in RL in
horse 2 (Table 5). In both cases, energy expenditure decreased
considerably after sedation (Fig. 3), without explanatory
changes in lung mechanics. This is most likely explained by
the extra energy expended by the horses in remaining alert:
although their feet remained stationary, their heads were held
high, and their muscles appeared tense. This extra muscular
effort without actual movement would not likely affect lung
function. Had we not sedated these horses, we would have
made an error in ascribing the “work of alertness” to the work
of breathing.
Also prospectively troublesome was the potential for xyla-
zine to cause bronchodilation, thus possibly obscuring the
effect of treatment with IB (4). Broadstone and coworkers (4)
examined the effect of xylazine in tracheostomized ponies with
acutely induced bronchoconstriction and found significant de-
creases in RL and increases in Cdyn. This reported finding has
the potential to affect the measurements made in this study,
because xylazine may bronchodilate such that further changes
in airway caliber would be undetectable. However, in the RAO
horses in our study, there were marked decreases in dPpl, RL,
Edyn, and RR, as well as an increase in VT after treatment with
IB (Table 3). Thus, although xylazine may indeed have in-
duced some bronchodilation in these horses, we were still able
to document significant changes in lung mechanics indicative
of bronchodilation after treatment with IB. We believe that
sedation is necessary to these measurements in client-owned,
nonaccustomed animals to increase ease and safety and to
achieve a truly resting measurement.
We used the abbreviated Weir equation to determine REE in
accordance with the American Association for Respiratory
Care (1) recommendations for indirect calorimetry. We recog-
nize that there are assumptions that must be made in using this
equation. Namely, in performing indirect calorimetry to deter-
mine REE, we are assuming that the substrates glycogen, lipid,
and protein disappear by direct oxidation at a given rate that
can be calculated, given measured V˙ O2, measured V˙ CO2, and
knowledge of the standard amount of O2 consumed and energy
produced during oxidation of each particular substrate. In using
the Weir equation, we assume that standard carbohydrate, fat,
Table 5. Calorimetry (V˙ O2, V˙ CO2, RQ, REE) and pulmonary function testing (RL, Cdyn, RR, VT, dPpl) in
control horses before and after sedation with xylazine
V˙ O2,
ml  kg1  min1
V˙ CO2,













Horse 1 NS 5.570.95 3.950.68 0.710.09 19.832.59 0.920.10 0.410.20 102.7 7.481.12 11.21.38
Horse 1 XS 3.930.28 2.950.26 0.750.06 14.150.91 0.910.16 520.66 8.01.9 8.221.42 10.024.8
Horse 2 NS 5.630.90 3.930.55 0.700.07 21.013.20 0.630.10 0.520.19 8.00.7 7.030.99 8.590.96
Horse 2 XS 4.010.21 3.050.15 0.760.03 15.190.78 0.900.11 0.610.56 8.02.5 7.542.39 8.692.05
Values are means  SD for 2 horses. RQ, respiratory quotient; NS, no sedation; XS, sedation with xylazine.
Fig. 3. V˙ O2 in a control horse before and after sedation with xylazine (0.5
mg/kg iv). V˙ O2 was markedly higher before sedation than after sedation. , No
sedation; F, after sedation.
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and protein are being consumed (30). This may lead to errors
if unusual substrates are being consumed or if gluconeogene-
sis, lipogenesis, or ketogenesis (as may be happening in the
cachectic state) is increased. We try to avoid these errors by
ensuring that the horse is eating a mixed carbohydrate-protein-
lipid ration (good-quality hay) and by standardizing with a
12-h fast before indirect calorimetry testing. Moreover, unless
unusual substrates are being consumed, these assumptions
potentially lead to more errors in accurately determining sub-
strate use, rather than overall energy production. We also
assume that the animal is not losing excessive amounts of
protein and that protein disappearance in horses, similar to the
case in humans, has a negligible effect on energy production as
measured by indirect calorimetry using the abbreviated Weir
equation (52).
An additional potential problem with this study is that horses
were not age matched. Basal metabolic rate decreases with age
in humans (56). Nonetheless, if there were a decrease in REE
in the older RAO horses, as is seen in humans, this should have
the effect of bringing their REE closer to that of the controls,
rather than having an elevated REE, as we observed. The
difference between the two populations might have been more
striking had they been age matched.
Unlike the loss of fat-free mass seen in humans with chronic
airway obstructive diseases (48), absolute fat-free mass did not
differ between control and RAO horses in this study. Rather,
RAO horses had a significantly decreased percentage of fat,
similar to humans and animals with chronic energy deficiency
(Table 1) (40). In contrast to the hypometabolism seen in
chronic energy deficiency, the RAO horses in this study were
hypermetabolic before bronchodilation, whereas after bron-
chodilation REE in RAO horses was not significantly different
from controls, although values in several individuals remained
high (Table 4). Although treatment with IB resulted in mea-
surable bronchodilation, there remained evidence of residual
obstruction (RL, Cdyn, and dPpl above control levels), sug-
gesting that the O2 cost of breathing might still be elevated
above normal (Table 3). There is evidence that humans with
the similar disease, COPD, experience an increase in REE due
to the biological effects of systemic inflammatory mediators
(10, 11, 53); this may be a contributor to the increased REE in
RAO horses, as well. Because we were unable to eliminate all
airway obstruction in these horses, it is impossible for us to
determine whether REE might actually be lower than control
values, similar to chronic energy deficiency, or whether inflam-
mation causes independent increases in REE.
Finally, it is important to note that indirect calorimetry has
the potential to play an important role both in the clinical
management of horses with cachexia associated with RAO and
as a tool for determining whole body response to bronchodi-
lator. The National Research Council (NRC) recommendation
for REE needs is based on the formula
REE (Mcal/day)
 0.975 0.21  body wt kg	/1,000 38	
For control horses, mean measured REE (9.48  3.04
Mcal/day) was not significantly different from NRC calcula-
tions (9.80  1.15 Mcal/day). In RAO horses, however, REE
measured by calorimetry (13.34  1.49 Mcal/day) was signif-
icantly higher than REE by NRC calculation (8.63  1.34,
Table 4).
Thus simple caloric imbalance is likely an important con-
tributor to body mass depletion in these horses.
Not only is indirect calorimetry a useful tool for clinical
assessment of dietary needs, it is also potentially valuable as a
method of assessing bronchodilation, because it is noninvasive
and well tolerated in the sedated horse and correlates well with
measurements of lung mechanics.
In conclusion, we find that the airway obstruction found in
horses with naturally occurring, severe, chronic RAO results in
increased energy expenditure and consequent weight loss, and
bronchodilation results in a significant decrease in REE. Base-
line pulmonary function is strongly correlated with energy
expenditure. Thus weight loss in this population is likely due to
an imbalance between increased energy expenditure due to
increased work of breathing and caloric consumption.
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